Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
© 2022 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
Close
© 2022 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
Close
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos
HomenewsMedicilon Events

Medicilon Events

Hot information：
Two Innovative Service Platforms of Medicilon were Selected as Shanghai International Service Trade Demonstration project| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon Assisted DAC Biotechnology's Fourth ADC Drug DXC007 Getting Approved for Clinical Use
Sep 26,2022
The foundation stone laying of Medicilon's subsidiary Medicilon (Baoshan) was successfully held
On September 21, 2022, Medicilon (Baoshan) Inc's, a subsidiary of Shanghai Medicilon Inc, groundbreaking ceremony was held in North Shanghai Parmaceutical Industrial Park. This is another grand event following the opening of Medicilon (Hangzhou) on September 7.
More
The foundation stone laying of Medicilon's subsidiary Medicilon (Baoshan) was successfully held
Sep 14,2022
Medicilon Subsidiary Medicilon (Hangzhou) Inc. Grandly Opened!
On September 7, 2022, the opening ceremony of Medicilon (Hangzhou) Inc., a subsidiary of Shanghai Medicilon Inc., was held in Hangzhou.
More
Medicilon Subsidiary Medicilon (Hangzhou) Inc. Grandly Opened!
Sep 14,2022
Medicilon was selected as "2022 Shanghai Top 100 Emerging Industry Enterprises" and "2022 Shanghai Top 100 Growth Enterprises"
On the afternoon of August 30, 2022, Shanghai Enterprise Confederation, Shanghai Entrepreneurs Association, Shanghai Economic Organization Federation and Jiefang Daily jointly held a press conference for the 2022 Shanghai Top 100 Enterprises in the China Financial Information Center.
More
Medicilon was selected as "2022 Shanghai Top 100 Emerging Industry Enterprises" and "2022 Shanghai Top 100 Growth Enterprises"
Sep 01,2022
Medicilon has been approved as the first batch of Group Open Innovation (GOI) for large enterprises in Pudong in 2022
Shanghai Medicilon Inc. was invited to attend the GOI press conference. The Medicilian Academician Innovative Drug Maturation Center was selected as the 2022 Pudong Large Enterprise Open Innovation Center.
More
Medicilon has been approved as the first batch of Group Open Innovation (GOI) for large enterprises in Pudong in 2022
Aug 29,2022
Medicilon Assists | Cullgen's class 1 new drug TRK degrader CG001419 was approved for clinical use
On August 8, 2022, Cullgen Inc announced the approval of the IND application for a TRK degrader (CG001419) for the treatment of advanced solid tumors. CG001419 is the world's first in class TRK (neurotrophic factor receptor tyrosine kinase) protein degrader.
More
Medicilon Assists | Cullgen's class 1 new drug TRK degrader CG001419 was approved for clinical use
Aug 15,2022
Medicilon was awarded the "Top 100 Listed Companies on the Sci-Tech Innovation Board in 2022"
Recently, the SMDC released the list of the "Top 100 Listed Companies on the Sci-Tech Innovation Board in 2022". With its strong scientific and technological innovation strength, Shanghai Medicilon Inc. stands out from many outstanding enterprises and ranks among the "Top 100 Listed Companies on the Sci-Tech Innovation Board in 2022".
More
Medicilon was awarded the "Top 100 Listed Companies on the Sci-Tech Innovation Board in 2022"
Aug 15,2022
Medicilon is listed in the 2022 China Biopharmaceutical Industry Value List "Top 20 Most Influential CXO Enterprises"
On August 4, 2022, the 6th China Bio-Pharma Partnering Forum 2022 and the 2022 China Biomedical Industry Value List Award Ceremony was held, Shanghai Medicilon Inc. was on the list of the "Top 20 Most Influential CXO Enterprise."
More
Medicilon is listed in the 2022 China Biopharmaceutical Industry Value List "Top 20 Most Influential CXO Enterprises"
Aug 01,2022
Medicilon has been listed in the 2021 "Top 20 CXO (including CDMO) Enterprises in China" for 4 consecutive years
On July 12, the 2021 "Top 20 CXO (including CDMO) Enterprise in China" selected by Menet was officially released, which once again demonstrated the professionalism and influence of a strong enterprises in China's pharmaceutical industries.
More
Medicilon has been listed in the 2021 "Top 20 CXO (including CDMO) Enterprises in China" for 4 consecutive years
Jul 11,2022
Medicilon and BravoBio have reached a strategic collaboration on innovative vaccine IND R&D services
On June 28, 2022, Shanghai Medicilon Inc. (Medicilon) and Shanghai BravoBio Co. Ltd. (BravoBio) signed a strategic collaboration agreement online to officially become the collaboration partner.
More
Medicilon and BravoBio have reached a strategic collaboration on innovative vaccine IND R&D services
Jul 11,2022
To assist preclinical research of RNA drugs, Medicilon and Acon Pharmaceuticals reached a strategic collaboration
On June 24, 2022, Shanghai Medicilon Inc. (Medicilon) and ACON Pharmaceuticals Inc. (ACON) reached a strategic collaboration.
More
To assist preclinical research of RNA drugs, Medicilon and Acon Pharmaceuticals reached a strategic collaboration
Jul 11,2022
Empowering gene therapy, Medicilon and ZY Therapeutics reach a strategic collaboration
On June 28, 2022, Medicilon and ZY Therapeutics signed a strategic collaboration on preclinical IND application services to jointly promote development of gene therapy drugs.
More
Empowering gene therapy, Medicilon and ZY Therapeutics reach a strategic collaboration
Jul 04,2022
Medicilon and Suzhou Langrui have reached a strategic collaboration
On June 19, 2022, Shanghai Medicilon Inc. and Suzhou Langrui Biomedical Co., Ltd. signed a strategic collaboration agreement on innovative drug research and development services.
More
Medicilon and Suzhou Langrui have reached a strategic collaboration
Stock Code
688202

Global

Address: 1 Broadway, Cambridge, MA02142 (America)

Tel: +1(626)986-9880(U.S. - West Coast)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 24, Seochojungang-ro 8-gril, Seocho-gu, Seoul, 06643 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2022 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
bioanalytical testing IND Filing PROTAC API ADME Drug Discovery Animal Models Oral Solid Dosage PDX model Pharmacokinetics More